Bepotastine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Bepotastine
Bepotastine.png
Systematic (IUPAC) name
4-[4-[(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid
Clinical data
AHFS/Drugs.com International Drug Names
MedlinePlus a610012
Pregnancy cat.
Legal status
  • Prescription only
Routes Oral, topical (eye drops)
Pharmacokinetic data
Bioavailability High (oral)
Minimal (topical)
Protein binding ~55%
Excretion Renal (75–90%)
Identifiers
CAS number 125602-71-3 N
ATC code None
PubChem CID 2350
DrugBank DB04890
ChemSpider 2260 YesY
UNII HYD2U48IAS YesY
KEGG D09705 YesY
ChEBI CHEBI:71204 N
ChEMBL CHEMBL1201758 N
Chemical data
Formula C21H25ClN2O3 
Mol. mass 388.88 g/mol
 N (what is this?)  (verify)

Bepotastine (Talion) is a 2nd-generation antihistamine.[1] It was approved in Japan for use in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name TALION. TALION was co-developed by Tanabe Seiyaku and Ube Industries, Ltd., who discovered bepotastine. In 2001, Tanabe Seiyaku granted Senju exclusive worldwide rights, with the exception of certain Asian countries, to develop, manufacture and market bepotastine for ophthalmic use. Senju, in turn, has granted the United States rights for the ophthalmic preparation to ISTA Pharmaceuticals, Inc., a specialty pharmaceutical company located in Irvine, CA.

References[edit]